[{"id":"fe52e481-e906-4f7f-a53f-550a7128a15c","acronym":"EVANGELINE","url":"https://clinicaltrials.gov/study/NCT05607004","created_at":"2022-11-07T13:56:21.386Z","updated_at":"2025-02-25T12:38:26.751Z","phase":"Phase 2","brief_title":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","source_id_and_acronym":"NCT05607004 - EVANGELINE","lead_sponsor":"Atossa Therapeutics, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 02/14/2023","start_date":" 02/14/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-24"},{"id":"db930c87-92ac-41c5-ad78-232d08feae0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00949598","created_at":"2021-01-18T03:41:34.600Z","updated_at":"2025-02-25T14:48:25.058Z","phase":"Phase 3","brief_title":"Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer","source_id_and_acronym":"NCT00949598","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" ER • PCNA","pipe":" | ","alterations":" ER positive","tags":["ER • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 177","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 10/01/2010","study_completion_date":" 10/01/2010","last_update_posted":"2025-02-13"},{"id":"d32e8658-c9d2-4f04-9c89-06bcade2de1e","acronym":"RxPONDER","url":"https://clinicaltrials.gov/study/NCT01272037","created_at":"2021-01-18T05:08:42.199Z","updated_at":"2025-02-25T16:36:08.722Z","phase":"Phase 3","brief_title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","source_id_and_acronym":"NCT01272037 - RxPONDER","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5018","initiation":"Initiation: 01/15/2011","start_date":" 01/15/2011","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2025-02-06"},{"id":"be7d6188-2112-45b6-8dd9-1605ed39cec6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04294225","created_at":"2021-01-18T20:50:11.614Z","updated_at":"2025-02-25T17:36:33.824Z","phase":"Phase 2","brief_title":"Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer","source_id_and_acronym":"NCT04294225","lead_sponsor":"Mayo Clinic","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole"],"overall_status":"Completed","enrollment":" Enrollment 161","initiation":"Initiation: 04/28/2020","start_date":" 04/28/2020","primary_txt":" Primary completion: 12/12/2022","primary_completion_date":" 12/12/2022","study_txt":" Completion: 12/12/2022","study_completion_date":" 12/12/2022","last_update_posted":"2025-01-28"},{"id":"ec583cea-b73e-4568-91d2-545510d640f1","acronym":"LEPRE","url":"https://clinicaltrials.gov/study/NCT05601700","created_at":"2025-02-25T18:07:59.797Z","updated_at":"2025-02-25T18:07:59.797Z","phase":"Phase 3","brief_title":"Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)","source_id_and_acronym":"NCT05601700 - LEPRE","lead_sponsor":"Ente Ospedaliero Ospedali Galliera","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 09/22/2022","start_date":" 09/22/2022","primary_txt":" Primary completion: 09/22/2029","primary_completion_date":" 09/22/2029","study_txt":" Completion: 09/22/2029","study_completion_date":" 09/22/2029","last_update_posted":"2025-01-27"},{"id":"072b5222-7280-4f30-8150-3b6f5d947d3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02228681","created_at":"2024-01-03T20:17:23.392Z","updated_at":"2025-02-25T15:41:52.541Z","phase":"Phase 2","brief_title":"Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer","source_id_and_acronym":"NCT02228681","lead_sponsor":"GOG Foundation","biomarkers":" PIK3CA • PGR • PTEN • CTNNB1","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation","tags":["PIK3CA • PGR • PTEN • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • letrozole"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 05/21/2015","start_date":" 05/21/2015","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 08/22/2024","study_completion_date":" 08/22/2024","last_update_posted":"2024-09-19"},{"id":"7377bb32-9626-4f5c-ab86-eedae4345f9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06086704","created_at":"2023-10-17T15:12:46.105Z","updated_at":"2024-07-02T16:34:59.744Z","phase":"Phase 2","brief_title":"Study of 18F-FFNP Breast PET/MRI","source_id_and_acronym":"NCT06086704","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2024-05-31"},{"id":"24e8ae9d-33b8-4686-b35a-14011c3c0cf0","acronym":"NAOMI","url":"https://clinicaltrials.gov/study/NCT04568616","created_at":"2021-01-18T21:49:14.275Z","updated_at":"2024-07-02T16:35:03.439Z","phase":"Phase 2","brief_title":"Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)","source_id_and_acronym":"NCT04568616 - NAOMI","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-15"},{"id":"e915b737-ffd0-45cb-831e-4df90b73590c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02206984","created_at":"2021-01-18T10:20:00.102Z","updated_at":"2024-07-02T16:35:03.969Z","phase":"Phase 2","brief_title":"Endocrine Response in Women With Invasive Lobular Breast Cancer","source_id_and_acronym":"NCT02206984","lead_sponsor":"Priscilla McAuliffe","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 201","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-14"},{"id":"924f441f-af1d-4089-89c9-8c65da31f6a6","acronym":"NCI-2021-12428","url":"https://clinicaltrials.gov/study/NCT05183828","created_at":"2022-01-11T17:56:17.517Z","updated_at":"2024-07-02T16:35:05.369Z","phase":"Phase 4","brief_title":"Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer","source_id_and_acronym":"NCT05183828 - NCI-2021-12428","lead_sponsor":"University of Washington","biomarkers":" HER-2 • ER • AR • HSD3B1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • AR • HSD3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/23/2022","start_date":" 01/23/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-07"},{"id":"4d2d76d4-435a-440f-8e0e-92bf66cb6dca","acronym":"NRG-GY019","url":"https://clinicaltrials.gov/study/NCT04095364","created_at":"2021-01-18T20:02:20.500Z","updated_at":"2024-07-02T16:35:06.502Z","phase":"Phase 3","brief_title":"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT04095364 - NRG-GY019","lead_sponsor":"NRG Oncology","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type • TP53 expression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 09/20/2019","start_date":" 09/20/2019","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-05-02"},{"id":"3f6cd9fc-5844-4b4e-b706-82899db0d8c4","acronym":"NSABP B-42","url":"https://clinicaltrials.gov/study/NCT00382070","created_at":"2021-01-18T01:19:44.480Z","updated_at":"2025-02-25T15:48:05.276Z","phase":"Phase 3","brief_title":"Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT00382070 - NSABP B-42","lead_sponsor":"NSABP Foundation Inc","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3966","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 08/25/2016","primary_completion_date":" 08/25/2016","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-22"},{"id":"d24439cc-d62c-48da-9580-3c9daa1b29b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05649956","created_at":"2022-12-14T14:58:11.091Z","updated_at":"2024-07-02T16:35:18.156Z","phase":"Phase 2","brief_title":"Letrozole in Uterine Leiomyosarcoma","source_id_and_acronym":"NCT05649956","lead_sponsor":"GOG Foundation","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-02-22"},{"id":"a86fbed9-c2b8-4113-b92e-528db0e786dc","acronym":"LIBER","url":"https://clinicaltrials.gov/study/NCT00673335","created_at":"2021-01-18T02:30:57.347Z","updated_at":"2024-07-02T16:35:18.439Z","phase":"Phase 3","brief_title":"Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation","source_id_and_acronym":"NCT00673335 - LIBER","lead_sponsor":"UNICANCER","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 05/01/2008","start_date":" 05/01/2008","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2024-02-21"},{"id":"77ea8bfe-82b7-4f8f-b1ad-84fe923e1875","acronym":"","url":"https://clinicaltrials.gov/study/NCT02583828","created_at":"2021-01-18T12:32:02.336Z","updated_at":"2024-07-02T16:35:20.321Z","phase":"","brief_title":"Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients","source_id_and_acronym":"NCT02583828","lead_sponsor":"Capital Medical University","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • letrozole"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2024-02-07"},{"id":"b0ab51f3-8aec-48cf-bc5f-a62cd48ff158","acronym":"","url":"https://clinicaltrials.gov/study/NCT01814397","created_at":"2021-01-18T08:03:14.685Z","updated_at":"2024-07-02T16:35:20.522Z","phase":"","brief_title":"Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients","source_id_and_acronym":"NCT01814397","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 07/01/2012","primary_completion_date":" 07/01/2012","study_txt":" Completion: 02/01/2013","study_completion_date":" 02/01/2013","last_update_posted":"2024-02-07"},{"id":"d6f98f26-2498-46cc-812f-de883aab657a","acronym":"PIONEER","url":"https://clinicaltrials.gov/study/NCT03306472","created_at":"2021-01-18T16:19:53.588Z","updated_at":"2024-07-02T16:35:21.649Z","phase":"Phase 2","brief_title":"A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer","source_id_and_acronym":"NCT03306472 - PIONEER","lead_sponsor":"Cambridge University Hospitals NHS Foundation Trust","biomarkers":" HER-2 • ER • CDH1 • CDH2","pipe":" | ","alterations":" ER positive • HER-2 negative • CDH1 expression","tags":["HER-2 • ER • CDH1 • CDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • megestrol"],"overall_status":"Completed","enrollment":" Enrollment 198","initiation":"Initiation: 07/20/2017","start_date":" 07/20/2017","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-01-30"},{"id":"77650eab-43cf-4fc1-b1f7-8de4c87fdc86","acronym":"TEXT","url":"https://clinicaltrials.gov/study/NCT00066703","created_at":"2021-01-18T00:09:39.799Z","updated_at":"2024-07-02T16:35:24.835Z","phase":"Phase 3","brief_title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","source_id_and_acronym":"NCT00066703 - TEXT","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" PGR","pipe":" | ","alterations":" HR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • exemestane • triptorelin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2672","initiation":"Initiation: 11/03/2003","start_date":" 11/03/2003","primary_txt":" Primary completion: 03/11/2011","primary_completion_date":" 03/11/2011","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-01"},{"id":"d6b8d28f-cf57-448e-abf6-4ebc22b10127","acronym":"SOFT","url":"https://clinicaltrials.gov/study/NCT00066690","created_at":"2021-01-18T00:09:39.396Z","updated_at":"2024-07-02T16:35:24.866Z","phase":"Phase 3","brief_title":"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","source_id_and_acronym":"NCT00066690 - SOFT","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" ER • PGR","pipe":" | ","alterations":" HR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • triptorelin • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3066","initiation":"Initiation: 12/17/2003","start_date":" 12/17/2003","primary_txt":" Primary completion: 05/01/2014","primary_completion_date":" 05/01/2014","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-01"},{"id":"c77ed8e3-c18d-4828-96c2-5ae77c3f1373","acronym":"","url":"https://clinicaltrials.gov/study/NCT03962647","created_at":"2021-01-18T19:29:53.696Z","updated_at":"2024-07-02T16:35:26.358Z","phase":"Phase 1","brief_title":"A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer","source_id_and_acronym":"NCT03962647","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-12-13"},{"id":"97d926d0-be37-423b-83a2-cb239072fda6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05464810","created_at":"2022-07-19T14:54:34.432Z","updated_at":"2024-07-02T16:35:27.090Z","phase":"Phase 1","brief_title":"Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05464810","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR • IL6 • TNFA • IL10 • TGFB1","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR • IL6 • TNFA • IL10 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2023-12-05"},{"id":"cb5e6196-e255-4624-9a78-03c6ecd17803","acronym":"NASBP-B-09","url":"https://clinicaltrials.gov/study/NCT06154590","created_at":"2023-12-04T19:17:15.344Z","updated_at":"2024-07-02T16:35:27.221Z","phase":"","brief_title":"Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor","source_id_and_acronym":"NCT06154590 - NASBP-B-09","lead_sponsor":"DR. DIANE CHISESI NFS. MD. PHD.","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • tamoxifen • cyclophosphamide • anastrozole • melphalan"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-12-04"},{"id":"56716229-bf25-4633-a712-b582f0be4f9a","acronym":"AIMSS","url":"https://clinicaltrials.gov/study/NCT01824836","created_at":"2021-01-18T08:06:30.206Z","updated_at":"2024-07-02T16:35:27.770Z","phase":"","brief_title":"A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)","source_id_and_acronym":"NCT01824836 - AIMSS","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" PGR","pipe":" | ","alterations":" PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1046","initiation":"Initiation: 06/11/2013","start_date":" 06/11/2013","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-11-29"},{"id":"1ad88123-0252-4396-b11e-03e4cec2a03f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00634634","created_at":"2021-01-18T02:21:42.930Z","updated_at":"2025-02-25T15:49:14.321Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer","source_id_and_acronym":"NCT00634634","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • letrozole"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 08/11/2008","start_date":" 08/11/2008","primary_txt":" Primary completion: 04/20/2019","primary_completion_date":" 04/20/2019","study_txt":" Completion: 04/28/2023","study_completion_date":" 04/28/2023","last_update_posted":"2023-11-09"}]